Replies to post #348719 on Innovation Pharmaceuticals Inc (IPIX)

[KMBJN]

I believe that more than 90% have surgery before CRT.

https://pubmed.ncbi.nlm.nih.gov/32861702/

Results: Among 1316 OSCC patients treated with curative-intent; 108 patients (8%) received non-operative management due to: medical inoperability (n = 14, 13%), surgical unresectability (n = 8, 7%), patient declined surgery (n = 15, 14%), attempted preservation of oral structure/function in view of required extensive surgery (n = 53, 49%) or extensive oropharyngeal involvement (n = 18, 17%).

Surgery is the main treatment modality for OSCC while postoperative radiation therapy (PORT) is indicated mainly for patients with advanced disease (e.g. pT3-4, pN2-3) or adverse pathologic/treatment features (e.g. close resection margin), and concurrent chemotherapy with PORT for patients with high risk features (positive microscopic resection margin[s] and/or pathologic extranodal extension) [1], [2], [3], [4], [5]

Almost everyone gets surgery if they can. The sooner the better.

Dr. Sonis didn't say anything about brilacidin other than the excerpt I posted. I don't know how he feels about it.

I think it's worth another trial if we have the money to risk. It is a big market, and there is a strong need for some drug to help.

Soligenix trial failed on top line for their phase 3 trial in December 2020. It looks like Sonis wrote the article in October 2020, so that's probably why he said no definitive results for a while. SGNX trial was the most advanced.

https://apnews.com/press-release/pr-newswire/business-technology-public-health-government-business-and-finance-health-care-policy-2a78c97ebf2e64fb5d3162a46b4e8cda

Will see if they go after secondary endpoints for approval or scrap the program.